Clinical Trial Update: EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source [Phase 2, Phase 3]

View source ↗

Summary

A randomized Phase 2/3 trial (EMPA-ESUS) is investigating whether empagliflozin improves left atrial function in patients with embolic stroke of undetermined so…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation New Onset
• Embolic Stroke of Undetermined Source

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: University of East Anglia | Conditions: Embolic Stroke of Undetermined Source, Atrial Fibrillation New Onset | Phase 2, Phase 3 | Status: RECRUITING